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ABSTRACT
The legalization of medical marijuana has highlighted cannabinoids as a
potential, opioid-free therapeutic option for pain management; however, the rise in
illicit synthetic cannabinoid-induced toxicity has demonstrated the need to outline
cannabinoid molecular signaling. The cannabinoid-type 1 (CB1) receptor is an
endogenous G protein-gated receptor (GPCR), well-expressed in the central
nervous system (CNS) associated with modulating neuronal activity. Cannabinoid
agonists bind to the CB1 receptor resulting in the inhibitory G protein (Gi) complex
to dissociate into two subunits, Gβγi and Gαi. The Gαi subunit inhibits adenylyl
cyclase, leading to a decrease in cyclic adenosine monophosphate (cAMP). The
Gβγi subunit activates G protein-gated inwardly-rectifying (GIRK) channels,
resulting in the efflux of potassium (K+) ions and the subsequent hyperpolarizing
of the neuron.
Cannabinoids are a group of compounds with a diverse range of chemical
structures. The primary cannabinoid classes are eicosanoid, classical, nonclassical, and aminoalkylindole. The aminoalkylindole cannabinoids represent a
large portion of illicit cannabinoids, or synthetic cannabinoid receptor agonists
(SCRAs), marketed as marijuana alternatives. Contrary to marijuana, intake of
SCRAs has toxic and sometimes, lethal consequences.
The following studies report: 1) a fluorescent GIRK channel assay sensitive
to CB1 receptor-mediated decrease in membrane potential. 2) analysis of the
v

GIRK channel response to cannabinoids representative of the four cannabinoid
classes 3) investigation of GIRK channel response to a selection of illicit SCRAs.
The cAMP levels were compared for AEA, THC, CP 55, 940, and WIN 55, 212-2,
in which all effectively suppressed cAMP. Cannabinoid potency across the primary
cannabinoid classes ranked: CP 55, 940 > WIN 55, 212-2 > THC > AEA > THCAA ≈ CBD. WIN 55, 212-2 (aminoalkylindole) was significantly more effective at
activating the GIRK channel response compared to AEA (eicosanoid) and THC
(classical). SCRAs had a rank order potency of 5-fluoro MDMB-PICA > 4-fluoro
MDMB-BUTINACA > AB-FUBINACA > MDMB-4en-PINACA > JWH-018 >
AM1220 > XLR-11 > JWH-122 N-(5-chloropentyl) > WIN 55, 212-2 > UR-144 >
AM1248. CBD did not induce a GIRK channel response. Synthetic cannabinoids
were more potent and effective at stimulating a GIRK channel response.
Indole/Indazole carboxamide substitutions displayed higher potencies. Only 4fluoro-MDMB-BUTINACA was significantly more efficacious at stimulating a GIRK
channel response compared to WIN 55, 212-2. Overall, synthetic cannabinoids
have greater GIRK channel potency and efficacy.
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CHAPTER 1: INTRODUCTION
1.1 The cannabinoid dichotomy
Chronic pain reduces the quality of life for many Americans, and the
standard treatment, opioids, are highly addictive.[3, 4] Prescription misuse
accounts for 40% of the opioid deaths in the United States, highlighting the need
for an alternative treatment.[3, 5, 6] Medical marijuana and cannabinoids have
become a popular candidate for opioid-free pain management.[7, 8] Since 1996,
33 states have legalized medical marijuana based on the reported therapeutic
effects in a variety of maladies, such as chemotherapy-induced emesis, glaucoma,
anxiety, and multiple sclerosis-related pain.[9, 10] In the early 2000s, synthetic
cannabinoid receptor agonists (SCRAs) began to appear on the drug market as
legal alternatives to marijuana.[11, 12] Academic laboratories developed many of
these compounds for the study of CB1 receptor binding and not for human use.[13]
Marijuana use has a high margin of safety; however, synthetic cannabinoid use
can cause stroke, acute kidney damage, psychosis, and seizures.[14, 15]
Cannabinoids have emerged as a forerunner in the race to develop better pain
management; however, the toxicity of synthetic cannabinoids has demonstrated
the need to understand how cannabinoids work.
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Cannabinoids as therapeutic targets
Humans have made products from the plant genus Cannabis for millennia,
with evidence of smoking Cannabis dating back to the first millennium BCE.[1618] The genus Cannabis is divided into three species: 1. Cannabis ruderalis 2.
Cannabis

indica

3.

Cannabis

sativa.[19]

Cannabidiol

(CBD)

and

Δ9-

tetrahydrocannabinol (THC) are the two most prominent compounds found in
Cannabis, with THC being the primary psychoactive and CBD the primary nonpsychoactive compound.[20, 21] Cannabis ruderalis contains low amounts of THC,
whereas Cannabis sativa and Cannabis indica have higher levels of THC.[19]
Marijuana is dried Cannabis sativa, Cannabis indica, or a combination of both, with
varying ratios of THC to CBD.[22] Tetrahydrocannabinolic acid (THCA) is another
cannabinoid found in Cannabis sativa. Fresh, unprocessed Cannabis sativa has
high THCA concentrations that are partially converted to THC when exposed to
heat.[23] Studies of THCA show potential therapeutic effects in pain, metabolic,
and neurological disorders.[22, 24, 25]
When surveyed, people reported a decrease in pain after smoking or
inhaling vaporized marijuana with low (≈4mg) to moderate (≈16mg) levels of
THC.[26-28] Currently, there are three cannabinoid pharmaceuticals reported to
decrease chronic pain.[29-32] Dronabinol and nabiximol are FDA-approved
pharmaceuticals derived from the Cannabis plant. Nabiximol contains THC and
CBD, whereas dronabinol only contains THC. [33] Nabilone is a synthetic analog
of THC approved as an adjunct treatment for pain.[10, 29] While some studies
report effective chronic pain relief with cannabinoid therapies, others report little to
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no anti-nociceptive effects when tested on other forms of pain, such as acute postoperative and abdominal pain.[10] A recent meta-analysis determined that the
effectiveness of cannabinoid-based pain therapeutics in humans inconclusive,
mainly due to studies lacking a positive control; however, research utilizing animal
models has found cannabinoids reduce pain reflexes and opioids selfadministration.[8, 10, 33, 34]
Adverse effects of illicit synthetic cannabinoid intake
In the early 2000s, SCRAs began appearing in shops as herbal incenses
under the names "K2", "Spice," and "Black Mamba."[35] Today, SCRAs products
are sold and distributed through the dark web, social media platforms, and
smartphone apps.[36] These products are created by spraying a mixture of SCRAs
on dried plant material, typically thyme or lemon balm, and then smoked like
marijuana.[12] Additionally, SCRAs are available in liquid formulations for use in
electronic cigarettes and other vaping devices.[37]
SCRAs bind to the same receptor as THC, the cannabinoid-type 1 (CB1)
receptor.[38] Unlike THC, SCRA intake can cause serious bodily harm such as
impairment of fine motor skills, increased blood pressure, tachycardia, tremors,
respiratory depression, seizures, ataxia, nausea, vomiting, acute kidney injury, and
death. [39-41] SCRAs typically produce more adverse psychological effects than
those experienced with THC, including impairments of attention and concentration,
anxiety, panic, agitation, paranoia, hallucinations, violent or aggressive behavior,
short-term memory loss and lack of responsiveness.[11, 42, 43] Researchers are
interested in the mechanisms underlying the differences between THC and SCRAs
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pharmacological effects, particularly regarding the CB1 receptor. Structural activity
relationship (SAR) studies show variation in SCRAs binding to the CB1 receptor.[2,
44, 45] These studies suggest that differences in CB1 receptor binding could
mediate SCRA potency and efficacy.
1.2 Cannabinoid-type 1 (CB1) receptor
The CB1 and cannabinoid-type 2 (CB2) receptors are the two predominant
receptors in the endocannabinoid system. The CB2 receptor is associated with the
peripheral nervous system (PNS) and immune response mechanism (i.e., glia) in
the central nervous system (CNS).[21, 46] The CB1 receptor is well-expressed in
CNS, particularly in the neocortex, hippocampus, basal ganglia, cerebellum, and
brainstem.[47] Primarily located on neuron axons, the CB1 receptor modulates
neuronal activity, such as inhibiting excitatory neurotransmitter release, through
the downstream effects of G protein signaling.[48-50]
CB1 receptor signaling
The CB1 receptor is a type-A, G protein-coupled receptor (GPCR)
consisting of seven transmembrane helices (TMH 1-7), three extracellular loops
(ECL1-3), three intracellular loops (ICL1-3), an N-terminus, and an intracellular Cterminus.[51] When the CB1 receptor is inactive, a heterotrimeric G protein
complex, Gαβγ, interacts with TMH5, TMH6, ICL2, and the c-terminus.[2] (Figure
1.1) A small opening between TMH1 and TMH7 allows for ligand entry into the
CB1 receptor. The suggested location of CB1 receptor orthosteric ligand-binding
pocket is in an area interacting with TMH2-3 and TMH6-7.[2, 45, 52] When an
agonist binds to the CB1 receptor, a conformation change occurs, and GDP is
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exchanged for guanosine triphosphate (GTP) at the Gα subunit.[53] The complex
dissociates into Gα and Gβγ subunits. These subunits initiate a series of
intracellular processes that mediate neuronal response.[54] There are three
principle G protein signaling pathways, Gs, Gi, and Gq. The actions of the Gα
subunit define the G protein signaling pathways. Gs stimulates the production of
cyclic-AMP (cAMP), whereas Gi inhibits the production of CAMP. Gq activates
phospholipase Cβ (PLCβ), leading to an increase in intracellular calcium (Ca 2+)
levels.[55] Also, signaling from the Gq pathway can initiate the synthesis of
endocannabinoids, anandamide (AEA) and 2-AG. [56]
Ligands binding to the CB1 receptor cause the recruitment of G proteingated receptor kinases (GRKs), which phosphorylate the receptor’s intracellular cterminus.[57] The phosphorylation of the CB1 receptor initiates the recruitment of
β-arrestin.[58, 59] (Figure 1.1C) The CB1 receptor recruits are two major β-arrestin
isoforms, β-arrestin 1 (βarr) and β-arrestin 2(βarr2). βarr1 activates downstream
signaling pathways that mediate gene expression and protein synthesis. βarr2 is
associated with CB1 receptor internalization and desensitization.[60-62] These
processes function to disrupt ongoing Gi signaling and stimulate cell apoptosis. βarrestins are often associated with adverse behavioral outcomes seen in
prolonged opioid and Cannabis use.[62-64] The CB1 receptor is defined as a Gi-coupled receptor
The CB1 receptor primarily couples the Gi signaling complex.[53, 65-67]
CB1 receptor agonists facilitate the release of Gαi, thus inhibiting adenylyl cyclase,
a key enzyme for the production of cAMP.[54] (Figure 1.2A) Both Gαi and Gβγi can
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regulate cellular processes like apoptosis, cell differentiation, and proliferation by
stimulating the mitogen-activated protein kinase (MAPK) signaling cascade.[68]
The Gβγi subunit inhibits N-type Ca2+ channels and activates G protein-gated,
inwardly-rectifying potassium (GIRK) channels. Activation of GIRK channels
allows for the efflux of potassium (K+) ions, driving the membrane potential towards
K+ equilibrium close to -90mV in neurons. (Figure 1.2B).[69-71]
1.3 Targeting GIRK channels
GIRK channels are ion channels composed of four inward rectifier K+ (Kir)
channel subunits, GIRK1 – GIRK4.[72] The GIRK1/2 subunit arrangement is wellexpressed throughout the CNS, specifically the hippocampus, cerebellum, and
spinal cord.[73] GPCRs activate GIRK channels through the Gβγi subunit, which
include muscarinic acetylcholine M2 (M2), dopamine-type 1 (D1), somatostatin
(SST), serotonin (5-HT1A), μ-opioid (MOR), and CB1 receptors.[74-78]
Ligands binding to GPCRs, such as MOR and CB1, initiate the release of
Gβγi from the Gαi subunit. The Gβγi subunit binds directly on the cytosolic side of
the GIRK channel to the c-terminus, which activates the channel.[79, 80] The GIRK
channel c-terminus can bind up to four subunits.[81] One Gβγi subunit binding to
the c-terminus will activate the GIRK channel, and the addition of each subsequent
Gβγi subunits will potentiate the GIRK channel response. The GIRK channel
response is deactivated when the Gαi, recouples to the Gβγi subunit.[76, 82]
Active GIRK channels will decrease spontaneous action potential formation
and inhibited the release of excitatory neurotransmitters.[72, 83] Analgesia is the
inability to perceive pain. Opioids, such as morphine, activate GIRK channels,

6

which mediate analgesic effects.[64, 84] The MOR-induced, GIRK channel
activation mediating analgesia serves as a potential mechanism by which CB1
receptor agonism could relieve pain.[84, 85]
1.4 Cannabinoids
Cannabinoid classification
Cannabinoids are compounds that act on receptors of the endocannabinoid
system.

The

CB1

and

CB2

receptors

are

considered

the

canonical

endocannabinoid receptors; however, cannabinoids can bind to other receptors
such as orphan G protein-gated receptor 55 (GPR55), Transient receptor potential
cation channel subfamily V member 1 (TRPV1), and Peroxisome proliferatoractivated receptors (PPARs).[21, 46, 86] Cannabinoids are categorized into
groups by their originating source and their chemical structure. Endocannabinoids
are cannabinoids synthesized within the body, in which the two primary ones are
AEA and 2-AG. The phytocannabinoid class consists of plant-derived
cannabinoids, such as THC and CBD. Synthetic cannabinoids are human-made
cannabinoids, be it in legitimate laboratories or illicit manufacturing outlets. The
first cannabinoids to have their chemical structure defined were from Cannabis
and,

therefore,

classified

as classical cannabinoids.

[87] Non-classical

cannabinoids share a similar structure to classical compounds; however, they are
synthetic cannabinoids. Eicosanoids are the structural class that includes
endocannabinoids. Aminoalkylindoles are synthetic cannabinoids that have a
unique chemical structure, unlike the previously listed.[88] (Table 1.1)
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Cannabinoid signaling
Cannabinoids signal through G protein-dependent mechanisms and βarrestin recruitment. The initial wave of cannabinoid signaling is primarily G
protein regulated.[62] In addition to the Gi pathway, cannabinoids also initiate
other G protein signaling pathways. While WIN 55, 212-2 signals mostly through
the Gi pathway, it can also induce the Gq signaling pathway.[89] In studies where
pertussis toxin (PTX) inhibited Gi, the aminoalkylindole, WIN 55, 212-2, could
recruit Gs and Gq signaling.[53, 66] Another study reported the illicit
aminoalkylindole derivatives, 5 fluoro-MDMB-PICA, JWH-018, and ABFUBINACA could also recruit the Gs signaling pathway.[90]
Cannabinoids show bias in recruiting either βarr1 or βarr2, which can
mediate different CB1 receptor signaling outcomes. For example, WIN 55, 212-2
bound CB1 receptors and β-arrestin briefly interact in the clathrin-coated pits
before receptor internalization, resulting in little to no βarr1 signaling. In
comparison, the endocannabinoid, 2-AG, has prolonged contact with the clathrin
coated-pits resulting in enhanced βarr1 signaling.[60, 61] Other studies
demonstrate that chronic exposure to THC induces CB1 receptor internalization
via βarr2 recruitment.[91, 92]
Recently, there is a growing interest in cannabinoid biased agonism. Biased
agonism is a concept stating that agonists can stabilize a receptor in different
active confirmations that allows them to preferential couple to the signaling
molecule.[93] Studies show THC is biased towards βarr1 recruitment over Gβγi
signaling; whereas AEA is biased toward Gβγi over βarr1.[94] For example, THC
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bound to the CB1 receptor alternates between two binding confirmations and
resulting in a less stable active confirmation.[2, 44] SCRAs do not fluctuate like
THC when bound; therefore, they are much more effective at stabilizing the CB1
receptor in the active conformation. Additionally, SCRAs bind deeper than THC in
the receptor which enables interacts with the twin toggle switch, a pair of residues
located on TMH3 and TMH6. Interaction with the twin toggle switch results in a
change in TMH6 that potentiates the exchange of GDP to GTP; and thus, initiating
CB1 receptor intracellular signaling.[2, 45, 52] It is postulated that cannabinoids
can stabilize active confirmations preferential to a specific G protein signaling
pathways or to a specific β-arrestin recruitment. Since pharmacological outcomes,
such as anti-nociception and tolerance, are associated with specific intracellular
signaling pathways, researchers are interested in identifying the active
confirmations that result in biased signaling.[95]
1.5 Synthetic cannabinoids
SCRAs are a diverse group of compounds with notably high affinity for the
CB1 receptor. In the 1990s, the three-point attachment hypothesis stated
cannabinoid receptor binding was contingent upon three THC moieties: 1) C9
methyl group 2) phenolic alcohol 3) pentyl side chain extending from C3. To test
the three-point attachment hypothesis, WIN 55, 212-2 was created and found to
have a higher affinity for the CB1 receptor in comparison to THC.[96] Because the
chemical structure of WIN 55, 212-2 was unlike the other cannabinoid classes, it
became the prototype cannabinoid for the aminoalkylindole class.[81] The
chemical structure of WIN 55, 212-2 served as a model for John W. Huffman and
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colleagues when they began synthesizing a group of naphthoylindole SCRAs. The
naphthoylindole, JWH-018, made headlines in the early 2000s when it was
identified in illicit substances marketed as legal alternatives to marijuana. Since
then, there has been an ongoing, legal battle between scheduling SCRA
compounds as illegal and the appearance of newly modified SCRAs that subvert
the law.
Today, the SCRA class is the most chemically diverse group of
cannabinoids. The vast number of SCRAs is attributed to two factors: 1) CB1
receptor binding is tolerant of structural modifications. 2) Synthesizing new
aminoalkylindole-derived SCRAs is, relatively, easy compared to other
compounds.[12, 97, 98] This has allowed for multiple reiterations of SCRAs,
tweaked to increase CB1 receptor potency and efficacy with unknown
consequences to human health. While categorizing such a large group of
compounds would seem a daunting task, SCRAs consists of four basic
pharmacophores: 1) core 2) linker 3) head group 4) tail group.[95] (Figure 1.3)
SCRAs cores are commonly either indole or indazole substitutions because this
increases the CB1 receptor potency.[99, 100]. Linkers are usually an amide,
ketone, or ester and do not appear to alter CB1 receptor potency. There are many
different head groups, but most contain a naphthyl, quinolinyl, adamantly, or
tetramethylcyclopropyl moiety.[101] Tail groups, typically, consist of a hydrophobic
alkyl group attached to the nitrogen atom of the head group.[11] The tail group can
have different substitutions, with the most common being the terminal fluorination
because it increases potency.[97, 102] (Table 1.2)
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Synthetic cannabinoid signaling
SCRAs are pharmacologically similar to THC; for example, JWH-018
decreases the probability of neurotransmitter release and stimulates MAPK
kinase, characteristics of CB1 receptor agonism.[103] Unlike THC, the use of
SCRAs increases the likelihood of seizures.[15] Like the cannabinoids discussed
in the previous section, SCRAs mediate their effects through CB1 receptor G i
signaling.[11] Almost all SCRAs are considered full agonists, as demonstrated by
enhanced Gi signaling effects such as inhibition of cAMP production and GIRK
channel activation in comparison to THC, a partial agonist.[99, 102, 104, 105] The
highly potent and toxic SCRA, MDMB-FUBINACA, is shown to hold the twin toggle
switch in a manner that stabilizes the CB1 receptor in the active conformation.[2,
45] The binding dynamics of cannabinoids are thought to mediate biased agonism,
which states a receptor can have multiple active state confirmations.[51] Increased
ligand interaction with` the twin toggle switch, located within the CB1 receptor,
increases the surface binding area critical for G protein binding.[45]
1.6 The impetus for this work
Cannabinoid research aims to bridge the gap between the receptor
signaling and the pharmacological response. Agonists of the CB1 receptor
stimulates Gi signaling, in particular, GIRK channels. Both cannabinoids and GIRK
channels have therapeutic promise when regarding pain management. However
the emergence of structurally diverse, illicit SCRAs highlights that there is much
still unknown about cannabinoid signaling.
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Hypothesis: Cannabinoid class and structure will differentially affect the GIRK
channel signaling via the CB1 receptor.
Aim 1: Establish a CB1 receptor GIRK channel assay
Aim 2: Determine the GIRK channel response to cannabinoids
representative of the eicosanoid, classical, non-classical, and
aminoalkylindole classes.
Aim 3: Investigate the effect of illicit SCRAs on GIRK channel activation
Each of these aims will be addressed in the following chapters.
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Figure 1.1: Structure of CB1 receptor with G protein complex Magenta: CB1
receptor Cyan: Gαi subunit Orange: Gβi subunit Purple: Gγi subunit Green:
scFv16 fragment used to stabilize CB1 receptor[2]
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A

C

B

Figure 1.2: CB1 receptor Gi & β- arrestin signaling. Cannabinoid ( ) bound
to the CB1 receptor releases intracellular Gβγi from Gαi and recruits βarrestin2 through receptor phosphorylation ( ). (A) Gβγi binds to and
activates GIRK channels, causing an efflux of potassium, (B) Gαi inhibits
adenylyl cyclase, leading to a decrease in cAMP. (C) β – arrestin2 is
recruited to phosphorylated CB1 receptor, causing a decrease in receptor
signaling (grey), and followed by receptor removal from the surface
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Table 1.1: Cannabinoid class and structure
Cannabinoid
Group
Endogenous

Cannabinoid
Class
Eicosanoid

Phytocannabinoids Classical

Cannabinoid Structure
AEA

CBD

THC

THCA-A

Synthetics

Non-classical

CP 55, 940

Aminoalkylindole WIN 55,
212-2
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Figure 1.3: Pharmacophore components of JWH-018. Commonly altered
areas on chemical structure that help categorize SCRA. Blue: Tail group
Orange: Core Green: Linker Black: Head group Modified from EMCDDA
2017[1]

16

Table 1.2: SCRAs class and structure
Aminoalkylindole-derived
SCRAs
Aminoalkylindole Prototype

Cannabinoid

Naphthoylindoles

JWH-018

WIN 55, 212-2

JHW-122 N(-5Chloropentyl)

AM1220
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Structure

Adamantoyloindole

AM1248

Tetramethylcyclopropylindoles UR-144

XLR-11

Indole carboxamide

5 fluoro-MDMBPICA

Indazole carboxamide

AB-FUBINACA
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4 fluoro-MDMBBUTINACA

MDMB-4enPINACA
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CHAPTER 2: ESTABLISHING THE CB1 RECEPTOR GIRK CHANNEL ASSAY
2.1 Abstract
The CB1 receptor can regulate neuronal activity through activating GIRK
channels.

The Walsh laboratory developed a real-time membrane potential

fluorescent assay for cannabinoids using pituitary AtT20 cells that endogenously
expressed GIRK channels and were stably transfected either with the CB1
receptor using a recombinant lentivirus (AtT20/CB1) or the CB1 receptor tagged
with super-ecliptic pHluorin (AtT20/SEPCB1).

In whole-cell patch-clamp

experiments application of the cannabinoid agonist WIN 55,212-2 to AtT20 cells
expressing the CB1 receptor (AtT20/CB1) activated GIRK currents that were
blocked by barium. WIN 55,212-2 activation of the GIRK channels was associated
with a time- and concentration-dependent (AtT20/CB1: EC50 309 nM,
AtT20/SEPCB1: EC50 523nM) hyperpolarization of the membrane potential in the
cells when monitored using a fluorescent membrane potential-sensitive dye. WIN
55,212-2 induced fluorescent signal was inhibited by pretreatment of AtT20/CB1
cells with the GIRK channel blocker tertiapin and in both AtT20/CB1 and
AtT20/SEPCB1 cells with the CB1 receptor antagonist SR141716. DMSO, the
solvent used in cannabinoid stock concentrations, did not elicit a GIRK channel
response. Together, this data supports the CB1 receptor, GIRK channel assay, as
an effective method for measuring cannabinoid-mediated, GIRK channel signaling.
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2.2 Introduction
The GIRK channel response is measured in a variety of cell types, with the
most recognized being the human embryonic kidney, or HEK-293, cells. There is
research suggesting that HEK-293 cells have different G protein expression levels
when compared to the CNS; hence, this study's use of the AtT20 cell line.[106]
AtT20 cells are an immortalized, mouse pituitary cell-line shown to have neuronal
properties and endogenously express the GIRK1/2 subunits.[78, 107]
Cannabinoids can suppress neuronal activity by stimulating GIRK
channels.[78] Changes in membrane potential can be measured by using a
microplate reader capable of detecting excitation and emission wavelengths and
fluorescent, membrane-potential sensitive (MP-sensitive) dye applied to cell
cultures.[108-110] The MP-sensitive dye molecules emit a fluorescent signal when
expressed in the intracellular space. (Figure 2.1A) Applying a CB1 receptor agonist
activates GIRK channels via the Gβγi subunit, resulting in the efflux K+ ions.
(Figures 2.1B & 2.1C) The efflux of the positive K + ions cause the MP-sensitive
dye molecules to move to the extracellular space where the fluorescent signal is
quenched. (Figure 2.1D) The microplate reader records the change in membranepotential-dependent fluorescence in real-time which is then quantified for
analysis.[108, 111, 112]
This study reports the development of a real-time assay for studying
cannabinoid-mediated Gβγi stimulation using MP-sensitive fluorescent dye. Clonal
AtT20 pituitary cells, which endogenously express the GIRK1/2 subunits, were
stably transfected with the unlabeled human CB1 receptor (AtT20/CB1) or the
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human

CB1

receptor

tagged

with

super-ecliptic

pHluorin

construct

(AtT20/SEPCB1) using lentivirus and subsequently studied using the whole-cell
arrangement of the patch-clamp technique and a fluorescent plate reader.
Application of WIN 55,212-2 to the AtT20/CB1 cells caused a time- and
concentration-dependent hyperpolarization of the AtT20 cell membrane potential
consistent with GIRK channel activation. The fluorescent signal produced by WIN
55,212-2 was inhibited by pretreating the cells with either the GIRK channel
blocker tertiapin or the CB1 receptor antagonist SR141716.

Therefore, the

AtT20/CB1 cell fluorescent assay will provide a valuable methodology for
determining the ability of various cannabinoid ligands to stimulate G i and activate
GIRK channels.
2.3 Material and methods
AtT20 cell culture and plating
The AtT20 pituitary cell line was obtained from ATCC (AtT-20/D16y-F2,
CRL-1795) and grown in DMEM media with 10 % fetal bovine serum + Pen-Strep.
Cells were plated on uncoated glass coverslips (5,000 cells per coverslip) (patchclamp recording) and in poly-l-lysine-coated wells of black 96-well plates (Corning
or Greiner) (30,000 cells per well) (fluorescent measurements). AtT20 cells were
stably transfected with lentivirus vectors containing either green fluorescent protein
(GFP) or the human cannabinoid type-1 (CB1) receptor (cDNA Resource Center)
that were supplied by Dr. Seungjin Shin (Viral Core Facility, University of South
Carolina). Cells were stored in an incubator at 37o C (5 % O2 / 95 % CO2) and
used on days 1-3 after plating. Cells expressing GFP were imaged using a Leica
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DM IL inverted microscope (Vashaw Scientiﬁc) and CoolSNAP EZ camera
(Photometrics) as described previously.[109] An additional set of AtT20 cells were
stably transduced with a lentivirus containing the SEPCB1 construct (courtesy of
Dr. Andrew Irving, University College Dublin) by Dr. Seungjin Shin (Viral Core
Facility, University of South Carolina). Cells were stored in an incubator at 37o C
(5 % O2 / 95 % CO2) and used on days 1-3 after plating as described previously.
[110]
Drugs and chemicals
Tertiapin was purchased from Alomone Laboratories (Jerusalem, Israel).
Cannabinoids were purchased for Cayman Chemical (Ann Arbor, Michagan).
Cannabinoid ligands were dissolved in DMSO at stock concentrations of 10-50mM
and diluted to various concentrations in 1 mM KCl buffer solution containing the
dye.
CB1 receptor immunoblot analysis.
AtT20 cells were harvested in RIPA lysis buffer (50 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5%
sodium deoxycholate, pH 7.4), and a protease inhibitor cocktail (Pierce Scientific).
The cell lysate was pulse sonicated at 2 watts using a model 100 sonic
dismembrator (Fisher Scientific) for two periods of 10 s separated by 1 min. The
protein content was determined by a Lowry assay. Western blotting was performed
by Dr. Gerardo G. Piroli, as described previously, with minor modifications.[113]
Briefly, cell lysates were added to the loading buffer and incubated for 5 min at
60°C. Samples were then resolved by SDS/PAGE, transferred to PVDF
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membranes and blocked for 1 hr at room temperature (RT) with 5% non-fat dry
milk in wash buffer (20 mM Tris pH 7.4 containing 0.05% Tween 20). Membranes
were then incubated at 4°C with a CB1 receptor Ab (guinea pig [gp] L15, a
generous gift of Dr. Ken Mackie, University of Indiana) in a 1:2000 dilution in 2%
non-fat dry milk in wash buffer. After 3 x 5 min washes with wash buffer,
membranes were incubated with a secondary Ab (rabbit anti-gp HRP,
Thermofisher) for 1 hr at RT, washed 3 x 5 min with wash buffer, developed with
Pierce ECL2 and exposed on X-ray films. Membranes were then incubated with
62.5 mM Tris stripping solution (pH 6.8) containing 2% SDS and 0.7% 2-mercapto
ethanol for 10 min at 65°C prior to re-probing with an Ab to actin (loading control)
(Santa Cruz Biotechnology).
Fluorescent, membrane-potential sensitive assay
GIRK channel activation was monitored in the 96-well plates by
fluorescently recording the cell membrane potential. [114, 115] and has been
described in detail [109]. For the membrane potential measurements, cells were
incubated for 30 min in normal buffer solution consisting of; 132 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM dextrose, 5 mM HEPES, pH 7.4 (with NaOH),
with a MP-sensitive fluorescent dye (FLIPR Membrane Potential kit RED or BLUE;
Molecular Devices). Prior to the fluorescent measurements, the cells were loaded
with dye in buffer solution containing 1 mM KCl and incubated for an additional 5
min.

Fluorescent signals were recorded using a Synergy2 microplate reader

(Biotek) at 28o C [115]. The cannabinoids or control solution (10 or 20 µl) were
added to each well (total volume = 110 or 220 µl) at time zero using an injector.
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Data points were collected at 5 s intervals over a 250 s sampling period at
excitation and emission wavelengths of 520 and 560 nm, respectively.
Patch-clamp recording.
The patch-clamp method was used to record the whole-cell, GIRK currents
using L/M EPC-7 (Adams & List Associates) and Axopatch 200 (Molecular
Devices) amplifiers.[116] Pipettes were made from borosilicate glass capillaries
(World Precision Instruments) and had resistances of 2-3 Mohms when filled with
an internal solution. All experiments were conducted on isolated, non-coupled
cells at room temperature (22-24 oC). GIRK currents were measured in external
solution consisting of; 95 mM NaCl, 50 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM
dextrose, 5 mM HEPES, pH 7.4 (with NaOH). High external K+ was used in order
to increase the driving force for K+ movement through the GIRK channel and allow
the measurements on inward GIRK currents. The internal solution consisted of;
50 mM KCl, 60 mM K+-Glutamate, 2 mM MgCl2, 1 mM EGTA, 2 mM ATP, 0.1 mM
GTP, 10 mM HEPES, pH 7.3 (with KOH). Following the measurement of the cell
background current, GIRK channels were activated by the addition of 2-5 μM WIN
55,212-2 using a perfusion system. In each experiment, the GIRK current was
defined as the BaCl2-sensitive current [115].
Data analysis
The WIN 55, 212-2 concentration versus response curve for the AtT20/CB1
cells was determined by fitting the data to a curve using a three-parameter, nonlinear regression (listed below) where the EC50 is the concentration producing a 50
% increase of the maximal response (Emax) and k is the slope factor.
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Three-parameter non-linear equation
𝑦=

𝐸𝑚𝑎𝑥
𝐷𝑟𝑢𝑔
(1 + 𝐸𝐶 )𝑘
50

The WIN 55, 212-2 concentration versus response curve for the
AtT20/SEPCB1 cells was determined by fitting the data to a curve using a fourparameter, non-linear regression (listed below) where the EC50 is the
concentration producing a 50 % increase of the ymax (Emax). Ymin is defined as a
minimum fluorescent GIRK channel response. Drug is the concentration, and
hillslope is the slope factor.

Four-parameter non-linear equation
𝑦 = 𝑦𝑚𝑖𝑛 +

𝑦𝑚𝑎𝑥 − 𝑦𝑚𝑖𝑛
𝐷𝑟𝑢𝑔
1 + ( 𝐸𝐶 )−𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒
50

2.4 Results
Development of a CB1 receptor MP-sensitive fluorescent assay
In previous studies, transfection of the AtT20 cells with the CB1 receptor
using traditional, liposome-based transfection procedures resulted in only weak
cannabinoid-stimulated GIRK currents and fluorescent signals [78, 117].
Therefore, in this study, the ATt20 cells were stably transfected with the CB1
receptor (AtT20/CB1 cells) using a recombinant lentivirus vector. As shown in
Figure 2.2A, the transfection of the AtT20 cells with a lentivirus vector containing
GFP resulted in fluorescence labeling in over 50 % of the imaged cells (n = 3 cell
cultures). The viral infection did not affect the morphology or viability of the cells.
Also, the viral-transfected cells stably expressed GFP for several months at a time
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with no additional treatment (virus, antibiotic, etc.) required. Immunoblot analysis
was carried out to confirm the expression of the CB1 receptor in the AtT20/CB1
cells (Figure 2.2B).

An immunoreactive band of approximately 50 kDa,

corresponding to the size of the full CB1 receptor, was identified in cell lysates
obtained from the AtT20/CB1 cells but not from untransfected, wild-type AtT20
cells (Figure 2.2B). A lower weight molecular weight band (≈ 30 kDa) was also
measured in the AtT20/CB1 cells (Figure 2.2B).
The AtT20/CB1 cells were next cultured in 96-well plates and loaded with
an MP-sensitive dye in 1 mM KCl buffer solution.

The presence of 1 mM

extracellular K+ established a gradient for K+ efflux out of the cells during GIRK
channel activation. Figure 2.1C plots the MP-sensitive fluorescent dye signal
measured over time in the AtT20/CB1 cells. The addition of WIN 55,212-2 to the
AtT20/CB1 cells caused a rapid, time-dependent hyperpolarization of the resting
membrane potential by allowing K+ efflux through the opened GIRK channels. As
anticipated, the application of WIN 55,212 to the wild-type AtT20 cells had no
hyperpolarizing effect on the membrane potential (Figure 2.2C).
Whole-cell patch-clamp experiments were performed to confirm that the
cannabinoid fluorescent signal resulted specifically from the opening of the GIRK
channels. Application of WIN 55,212-2 to the AtT20/CB1 cells resulted in the
activation of an inward rectifying K+ current, which was inhibited by 1 mM BaCl2, a
GIRK channel blocker (n = 7 cells) (Figure 2.3 A & B). The properties of the
cannabinoid-activated Kir current are consistent with GIRK channels previously
recorded during somatostatin stimulation.[109, 114, 117]
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Establishing the CB1 receptor-induced GIRK channel assay using AtT20/CB1 cells
Using the fluorescent assay for measuring cannabinoid signaling, the
pharmacological properties of the expressed CB1 receptor were examined. As
shown in Figure 2.4B, WIN 55,212 activated the AtT20/CB1 cell fluorescent signal
with a half-maximal effective concentration (EC50) of 309nM. Maximal stimulation
occurred in the presence of a 2-5μM WIN 55, 212-2 (Figure 2.4A). The fluorescent
signal was also measured following pretreatment of the cells with either tertiapin,
a selective blocker of Kir channels, or the CB1 receptor antagonist SR141716 [118,
119].

As shown in Figures 2.4C and 2.4D, five minutes of exposure of the

AtT20/CB1 cells to either tertiapin or SR141716 strongly inhibited the subsequent
WIN 55,212-2 fluorescent signal.
It is worth noting the increase in fluorescent signal in Figure 2.2C and 2.3A
has been documented in previous research.[108, 117] As state in the MP-Red dye
manual (Molecular Devices), this is most likely a result of cells detaching from the
bottom of the wells. This issue was later resolved using AtT20/SEPCB1 and MDBlue dye discussed in the next subsection.
Confirming

CB1

receptor-induced,

GIRK

channel

response

using

the

AtT20/SEPCB1 cell line
The previous experiment was repeated to confirm that the GIRK channel
signal could be reliably measured in AtT20/SEPCB1 through CB1 receptor
agonism. A concentration of 10µM WIN 55, 212-2 produced the largest GIRK
channel signal in AtT20/SEPCB1 cells using the MP-BLUE dye. (Figure 2.5A) The
WIN 55, 212-2 mediated, GIRK channel response had an EC50 of 523 nM.
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(Figure2.5B) The pretreatment of 1μM SR141716 inhibited the WIN 55, 212-2
induced, GIRK channel. (Figure2.5C) A concentration representing the largest
volume of DMSO exposed to AtT20/SEPCB1 cells in the following chapters was
tested to screen for off-target effects. DMSO (0.1%) did not elicit a GIRK channel
response. (Figure 2.5D)
2.5 Discussion
This study describes a novel methodology for examining the action of CB1
ligands on Gi signaling. This assay is based on the use of a fluorescent MPsensitive dye to measure cell membrane hyperpolarization during G i-mediated
activation of GIRK1/2 channels in pituitary AtT20 cells. [114, 115] Previous studies
have demonstrated that the CB1 receptor can be expressed in the AtT20 cells
using liposome-based transfection procedures and used to measure GIRK
channels in the presence of WIN 55,212-2. [78] However, both the reported WIN
55,212-2 activated GIRK currents and MP-sensitive fluorescent signals were small
compared with those measured during stimulation of the endogenous SSTR with
somatostatin [114, 115, 117]. To overcome this problem, the CB1 receptor was
expressed using a recombinant lentiviral vector.

With this approach, sizable

inward rectifier K+ currents (mean = 9 pA/pF at -100 mV) and fluorescent signals
were measured in the AtT20/CB1 cells during activation with WIN 55,212-2
(Figures 2.2 & 2.3). The inhibition of the cannabinoid fluorescent signal by the
GIRK channel blocker, tertiapin, strongly suggests that the hyperpolarization
caused by WIN 55,212-2 results from the opening of GIRK channels.
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WIN 55,212-2 is a synthetic aminoalkylindole cannabinoid that has been
widely utilized in the study of the CB1 receptor. [53, 66, 88, 94] Van der Lee et al.
(2009) carried out several cellular assays, including β-arrestin recruitment and
cAMP accumulation assays with the CB1 receptor expressed in heterologous cell
lines.[120] The EC50 for WIN 55,212-2 in these assays ranged from 6 to 213 nM
with maximum cannabinoid effects occurring at a concentration of 1 μM and above.
More recently, cannabinoid signaling was studied in a mouse cell culture model of
striatal medium spiny projection neurons that endogenously express CB1
receptors.[121] Bioluminescence resonance energy transfer (BRET) was utilized
to quantify direct interactions of the CB1 receptor and βarr2 following ligand
binding. Using this system, the BRET EC50 for WIN 55,212-2 was 650 nM with
maximal effects requiring concentrations of WIN 55,212-2 between 1 and 10 μM.
[121] Thus, the EC50 and maximal effects of WIN 55,212-2 observed in both the
establishing and modified GIRK channel assays are consistent with those reported
using other methodologies. Also, cannabinoid antagonist SR141716 sufficiently
inhibited the WIN 55,212-2-induced GIRK channel response in both assays.
(Figure 2.3).
In summary, a MP-sensitive, fluorescent GIRK channel assay was
developed to measure Gi- activation of GIRK channels in AtT20 cells expressing
the CB1 receptor. Biased receptor agonists, drugs that preferentially activate G
protein signaling or β-arrestin recruitment, have become a primary focus of
therapeutic research efforts.[122] Recently, the compound TRV130 was identified
as a µ-opioid agonist that displays an efficacy for Gi stimulation equal to that of
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morphine, but without promoting morphine-mediated β-arrestin recruitment and µopioid receptor internalization.[64] In the mouse brain, different CB1 receptor
agonists act in a biased manner to selectively activate different inhibitory and noninhibitory G protein subunits.[89] Therefore, the CB1 receptor, GIRK channel
fluorescent assay may be useful for identifying CB1 receptor agonists that are
biased for Gi signaling.
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Figure 2.1. Schematic of fluorescent, membrane potential GIRK channel assay.(A) During
AtT20/CB1 or AtT20/SEPCB1 cell resting state, Molecular Devices dye D is distributed
intracellularly and produces a fluorescent signal. (B): Binding of CB1 agonist, WIN 55, 212 (WIN)
results in the intracellular, Gβγ protein subunit to disassociate and bind to GIRK, thus activating the
channel. (C) Activation of GIRK channels results in an efflux of potassium ions (K +), thus causing
resting membrane potential to become more negative, hyperpolarizing the cell. (D) The shift
towards a more negative membrane potential causes the dye to move to the extracellular space,
thus quenching the fluorescent signal.

A

B

C

Figure 2.2: Stable expression of GFP and the CB1 receptor in AtT20 cells using
lentivirus vectors. A: Fluorescent image of AtT20 cells infected with lentivirus
expressing did not impact cell viability or cause abnormal cellular changes. B:
Immunoblots for the CB1 receptor in AtT20 cells infected with lentivirus
expressing the CB1 receptor (AtT20/CB1 cells) or non-transfected wild-type cells
(wt AtT20 cells). Immunoblots obtained with an Ab to actin (bottom panel)
demonstrated equal protein loading in the lanes. C: MP-sensitive dye fluorescent
intensities obtained n AtT20 cells in the presence of absence of WIN 55, 212-2
(2μM) (WIN). The ratio of the fluorescent intensity (F/F0) was calculated by
dividing the signal measured in the presence (F) of WIN by the baseline signal
measured before (F0) addition of WIN. Each point represents the mean ± S.E.M
obtained in 87 wells containing AtT20/CB1 cells and 12 wells containing wt AtT20
cells. WIN was added at time zero (↓)
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A

B
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Figure 2.3: CB1 receptor stimulation activates GIRK channels in AtT20/CB1 cells. A: Representative AtT20/CB1 wholecell current traces obtained during voltage steps applied from a holding potential of −40 mV to −100, −90, −80, & −70
mV before (control) and after the addition of 5 μM WIN 55,212-1. B: Current versus voltage relationship illustrating WIN
55,212-1 activation of an inward rectifying K+ current that was blocked by Barium chloride. Each point represents the
mean ± S.E.M obtained in seven AtT20/CB1 cells.
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Figure 2.4: WIN 55,212-2 stimulates the GIRK channel fluorescent signal in a
concentration-dependent manner. (A) Changes in the MP-sensitive dye (MPRED) fluorescent signal following injection of WIN 55,212-2 in wells containing
the AtT20/CB1 cells. Each point represents the mean ± S.E.M obtained in 9–12
wells. (B) Concentration versus response curve for the WIN-sensitive
fluorescent signal. The concentration-response curve was obtained by fitting the
maximum responses from A to a three-parameter non-linear regression, where
the EC50 is the concentration of WIN producing a 50% increase in the maximal
response.(C) Cells pretreated with GIRK channel blocker, tertiapin, inhibited
GIRK signal. (D) Cells pretreated with CB1 receptor antagonist, SR141716,
inhibited GIRK channel signal. WIN was added at time zero (↓).
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Figure 2.5 GIRK channel assay using MP-Blue dye and AtT20/SEPCB1
cells. (A) Changes in the MP-sensitive dye (MP-BLUE) fluorescent signal
following injection of WIN 55,212-2 in wells containing the AtT20/SEPCB1
cells. Each point represents the mean ± S.E.M obtained in 4–8 wells. (B)
Concentration versus response curve for the WIN-sensitive fluorescent
signal. The concentration-response curve was obtained by fitting the
maximum responses from A to a four-parameter non-linear regression,
where the EC50 is the concentration of WIN producing a 50% increase in
the maximal response.(C) Cells pretreated with CB1 receptor antagonist,
SR141716, inhibited GIRK channel signal. (D) DMSO does not induce a
GIRK channel signal. Error bars are presented as ± S.E.M. WIN 55-2122 or DMSO was added at time zero (↓)
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CHAPTER 3: ANALYSIS OF GIRK CHANNEL RESPONSE TO
CANNABINOIDS REPRESENTATIVE OF THE FOUR CLASSES
3.1 Abstract
Cannabinoids uniquely bind to the CB1 receptor, potentially mediating the
int. CB1 receptor agonists precipitate the release of the Gβγi subunit, which then
binds to and activates GIRK channels. This study investigates GIRK channel
responses to representatives from the following cannabinoid classes: eicosanoid,
classical, non-classical, and aminoalkylindole. Using cultured AtT20/SEPCB1
cells, GIRK channel assays were performed with the following cannabinoids:
anandamide

(AEA),

CP

55,

940,

Δ9-tetrahydrocannabinol

(THC),

Δ9-

tetrahydrocannabinolic A (THCA-A), cannabidiol (CBD), and WIN 55, 212-2. Also,
cAMP levels were recorded for AEA, CP 55, 940, THC, and WIN 55, 212-2 using
AtT20/CB1 cells. All of the cannabinoids were effective at suppressing cAMP
production. When measuring the GIRK channel response, the cannabinoids
displayed a rank order potency of CP 55, 940 > WIN 55, 212-2 > AEA > THC.
Phytocannabinoids, THCA-A and CBD, were excluded from further analysis
because both failed to stimulate a GIRK channel response. Emax values were
determined by normalizing the cannabinoids peak GIRK channel signal to WIN 55,
212-2. The only comparison to not reach significance was CP 55, 940 vs. WIN 55,

38

212-2. This study demonstrates that synthetic cannabinoids elicit a stronger GIRK
channel response, which could potentially be due to CB1 receptor binding.
3.2 Introduction
While cannabinoids are commonly defined by their source (i.e., plants,
body, or laboratory), the chemical structure is an equally important characteristic
used to categorize the diverse range of compounds.[88] The eicosanoid, AEA, is
a unique neurotransmitter as it is produced as needed and targets presynaptic
CB1 receptors where it functions to decrease neurotransmitter release.[21] Recent
changes to legal policies regarding marijuana have highlighted many classical
cannabinoids, including THC, CBD, and THCA.[123] CP 55, 940 is a non-classical
cannabinoid that lacks the pyran ring seen in classical cannabinoids.[104] Initially,
Pfizer developed CP 55, 940 in 1974 as a non-opiate analgesic; however, it has
since become a commonly used tool in cannabinoid studies.[124] WIN 55, 212-2
was developed by Sterling Research Institute as a tool to study CB1 receptor
binding and is the prototype cannabinoid in the aminoalkylindole class. Like CP
55, 940, WIN 55, 212-2 is a well-known cannabinoid in cannabinoid research. [124126]
CB1 receptor agonists can stimulate different G protein signaling pathways
and β-arrestin recruitment and also vary in the magnitude of stimulation for these
signaling pathways.[53, 121, 127] WIN 55, 212-2 and AEA are considered full CB1
receptor agonists. THC is partial agonist due to being less effective initiating Gαi
signaling when compared to WIN 55, 212-2 and AEA.[53] Despite both being full
agonists at the CB1 receptor, WIN 55, 212-2 and CP 55, 940 had plasmon-
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waveguide resonance (PWR) shifts in opposite directions, which suggested that
they had unique CB1 receptor active confirmations.[128] This was later supported
by Hua et al. (2016) that demonstrated that WIN 55, 212-2 and CP 55, 940 had
unique CB1 receptor binding characteristics.[44] In the presence of PTX, many
cannabinoids can stimulate Gs.[90] Specifically, CP 55, 950 can recruit Gs
signaling and is more effective at recruiting Gs over WIN 55, 212-2.[121, 129] Since
the Gs signaling pathway opposes the Gi signaling pathway; therefore,
downstream effects of active Gs signaling would attenuate the G i-dependent
intracellular responses. In the context of these experiments, more G s signaling
could proportionately suppress the GIRK channel response by counteracting the
decrease in membrane potential.
These sets of experiments aimed to establish an outline of CB1 receptorinduced, GIRK channel responses to cannabinoid compounds selected from the
four

major

structural

classes:

eicosanoid,

classical,

non-classical,

and

aminoalkylindole. These results highlighted potential differences in Gβγi subunit
signaling, which served as a resource in delineating the results in the following
chapter.
3.3 Materials and methods
Cell culture and assay
AtT20/SEPCB1 cells were cultured in 96-well plates (Greiner), as previously
discussed in chapter 2. AtT20/CB1 cells were cultured in clear, 6-well plates and
stored in an incubator at 37o C (5 % O2 / 95 % CO2) and then used for cAMP
measurements 3 to 4 days later.
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cAMP assay
Forskolin is a compound used in experiments to increase cellular cAMP
levels. 3-isobutyl-1-methylxanthine (IBMX) is added to inhibit phosphodiesterase
degradation of cAMP to potentiate forskolin-induced cAMP production.[130, 131]
Using a cAMP enzyme-linked immunosorbent assay (Direct cAMP ELISA kit,
Enzo), AtT20/CB1 cells were first exposed to a cannabinoid, then forskolin and
IBMX. cAMP levels were measured in the following conditions: 1) Control 2) cAMP
generation (forskolin & IBMX) 3) CB1R stimulated (Cannabinoid + Forskolin &
IBMX). Absorbance was read on a Synergy2 microplate reader (Biotek). N values
in this assay represent the number of wells tested.
Drugs and chemicals
Arachidonoyl ethanolamide (Anandamide/AEA), CP 55, 212, cannabidiol
(CBD), ∆9-tetrahydrocannabinol (THC), Δ9-Tetrahydrocannabinolic acid A (THCAA), and WIN 55, 212-2 were all purchased from Cayman Chemicals (Ann Arbor,
Michigan). CBD and THC were purchased with the Walsh Laboratory DEA license.
Cannabinoids were dissolved in DMSO at stock concentrations of 40mM 50mM. AEA was purchased pre-diluted in alcohol at 145mM. All cannabinoids
were diluted to working concentrations in 1 mM KCl buffer solution containing MDBLUE dye (Molecular Devices).
Data analysis
Concentration curves were determined using four-parameter, non-linear
regression analysis where EC50 is the concentration producing a 50 % increase in
the maximal response ymax (Emax). (listed below) Ymin is defined as a minimum
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fluorescent GIRK channel response. Drug is the concentration, and hillslope is the
slope factor.
Relative Emax values were determined by normalizing each cannabinoid
maximal GIRK channel response to the maximal GIRK channel response of WIN
55, 212-2 (10μM). “n” represents the number of wells in which that cannabinoid
concentration was tested.
Four-parameter Equation
𝑦 = 𝑦𝑚𝑖𝑛 +

𝑦𝑚𝑎𝑥 − 𝑦𝑚𝑖𝑛
𝐷𝑟𝑢𝑔
1 + ( 𝐸𝐶 )−𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒
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Statistical analysis
Statistical analysis of maximal GIRK channel response was completed
using one-way, multiple measures ANOVA. Significance was set at p < .05. Posthoc analysis was completed using Holms-Ŝídák. All data analyses were performed
using Sigmaplot 14.0.
3.4 Results
All cannabinoids tested suppressed cAMP in the presence of forskolin and
IMBX, which is consistent with previous studies.[78] (Figure 3.1) It is worth noting
the cAMP levels were measured using AtT20/CB1 cells and were recorded prior
to the GIRK channel assays. Later cAMP experiments were inconsistent and were
further complicated by problems with the AtT20/CB1 cells; however, the reported
results align with previous studies and are presented here to demonstrate Gαi
signaling.[78, 129]
Maximum GIRK channel responses for THC, THCA-A, and CBD were
compared to 2μM WIN 55, 212-2. (Figure 3.2 A-D) The concentration of WIN 55,
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212-2 was set at 2μM, a reference concentration determined by previous
experiments performed in the Walsh laboratory.[111] CBD did not activate GIRK
channels at any concentration, whereas the THCA-A GIRK channel response was
marginal. (THCA-A: 1nM - 1µM, CBD: 1nM - 10µM) (Figure 3.2E).
A dose-dependent, GIRK channel response was recorded for the following
cannabinoids: AEA (n = 4), CP 55 940 (n = 7), THC (n = 9), and WIN 55, 212-2 (n
= 5). (Figure 3.3 A-E) An EC50 figure displaying WIN 55, 212-2, THC, AEA, and
CP 55, 940 was created to demonstrate the differences in cannabinoid potencies
better. (Figure 3.3 F). Emax curves generated by normalizing the peak GIRK
channel response for the cannabinoids to the maximum WIN 55, 212-2
concentration (10µM). The cannabinoid curves in the Emax comparison graph was
generated by running a four-parameter global regression analysis with minimum
values shared.[132] (Figure 3.3F).
The rank order potency was CP 55, 940 > WIN 55, 212-2 > AEA > THC >
THCA-A ≈ CBD. WIN 55, 212-2 produced the maximum GIRK channel response
at a concentration of 10μM. Maximal AEA and THC GIRK channel responses were
significantly lower when compared to WIN 55, 212-2. CP 55, 940 produced a
maximal GIRK channel response slightly less, but not significantly different, than
WIN 55, 212-2. (Table 3.1)
3.5 Discussion
The cannabinoids in this study exhibited differential GIRK channel
responses. The synthetic cannabinoids, WIN 55, 212-2, and CP 55, 940, were the
most efficacious at eliciting a GIRK channel response. The absence of a CBD-
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induced, GIRK channel signal suggests CBD is not a CB1 receptor agonist.
Research suggests that CBD does not directly activate the CB1 receptor; instead,
evidence supports CBD as a negative allosteric modulator of CB1 effective for
regulating CB1 receptor agonist effects.[51, 133] THCA-A exhibited a slight GIRK
channel signal; however, this is likely THC. THCA-A undergoes decarboxylation
into THC, and previous studies report THC contamination as a result of THCA-A
instability.[123]
The results of this study are reflective of CB1 receptor binding and signaling
across the four primary cannabinoid classes. In this study, the THC-induced, GIRK
channel response is consistent with CB1 receptor partial agonism.[88] AEA was
less potent than THC, suggestive of less Gβγi subunit signaling; however, it was
significantly more effective than THC at stimulating the GIRK channel response.
Previous research has reported AEA as having a greater Gβγi signaling-dependent
response compared to THC.[53, 94, 128] This could account for the more effective
GIRK channel response for AEA, despite the lower potency.
AEA was significantly less effective at stimulating a GIRK channel response
in comparison to CP 55, 940, and WIN 55, 212-2. In a study by Laprairie et al.
(2014), AEA was preferential towards the Gq signaling pathway over THC, WIN
55, 212-2, and CP 55, 940.[121] The reduced GIRK channel response could be
attributed to Gq -related increases intracellular Ca2+ levels causing an increase in
the membrane potential in contrast to GIRK channel activity.[134] While CP 55,
940 was approximately 4x more potent that WIN 55, 212-2, it was not significantly
more effective at stimulating a GIRK response. βarr2 recruitment modulates
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agonist-induced, CB1 receptor internalization and desensitization.[135] In a study
by Ford et al. (2017), βarr2 was actively recruited by CP 55, 940 [136] The rapid
desensitization would extinguish the GIRK channel signal; therefore, reducing the
effectiveness of CP 55, 940.
In conclusion, the analysis of the cannabinoids revealed that synthetic
cannabinoids elicited a more significant GIRK channel response compared to
phytocannabinoids and AEA. Of interest, CP 55, 940 was more potent than WIN
55, 212-2, but equally as effective in activating the GIRK channel response.
Observing these results together suggests that the cannabinoid chemical structure
could modulate the GIRK channel response. Investigation of synthetic cannabinoid
mediated, GIRK channel response could provide further insight into the
relationship between cannabinoid structure and cellular response.
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Figure 3.1: cAMP levels across cannabinoids. WIN 55, 212
and AEA suppress cAMP more effectively than CP 55, 940
suggestive of potential Gi signaling differences. Error bars
represent standard error of mean. Control (n = 24) Forskolin
& IBMX (n = 24), 2μM WIN 55, 212 (n = 24) 10μM THC (n =
6) 10μM AEA (n = 6) 1μM CP 55, 940 (n = 6)
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Figure 3.2: Non-psychoactive, classical cannabinoids do not induce GIRK
response. Stronger GIRK channel response with structurally unique
aminoalkylindole, WIN 55, 212-2, than psychoactive classical cannabinoid,
THC. A) WIN 55, 212-2 B) THC C) THCA-A D) CBD E) GIRK channel responses
comparing classical non-psychoactive and psychoactive cannabinoids to an
aminoalkylindole Error bars represent standard error of mean.↓ Indicates drug
application THC (n = 9), CBD (n = 6), THCA-A (n = 5), WIN 55, 212-2 (n = 6)
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Figure 3.3: GIRK channel responses for general cannabinoids and cannabinoid
structures. (A) WIN 55, 212-2 (B) THC (C) AEA (D) CP 55, 940 (E) Comparison
of max GIRK channel responses. (F) Comparison of EC50 demonstrating
cannabinoid potency G) Comparison of cannabinoid Emax relative to WIN 55, 2122 Error bars represent ±S.E.M.↓ Indicates application of WIN 55, 212-2 (n = 5),
THC (n = 9), AEA (n = 4), CP 55, 940 (n = 6)
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Table 3.1: Potency and efficacy of four general cannabinoids
Class

Cannabinoid

EC50 (nM)
± S.E.M

Emax (%)
± S.E.M.

Aminoalkylindole

WIN 55, 212-2

522.9 ± 68.0

Reference

Eicosanoid

AEA

4252.0 ± 801

31.2 ± 4.27*

Classical

THC

1140.7 ± 139

21.6 ± 2.78*

CP 55, 940

124.9 ± 41.2

98.3 ± 2.39

Non-classical

* p < 0.001 compared to WIN 55, 212-2
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CHAPTER 4: GIRK CHANNEL RESPONSES TO SYNTHETIC
CANNABINOIDS
4.1 Abstract
The discovery of new synthetic cannabinoid receptor agonists (SCRAs) in
illicit products marketed as alternatives to marijuana continues today. The intake
of these substances adversely affects human health. Currently, there is no
treatment for SCRA overdose. Illegal manufacturers will produce SCRAs with
increased cannabinoid-type 1 (CB1) receptor potency and efficacy due to
alterations made to the chemical structure. The Gβγi subunit released from the
CB1 receptor G protein complex triggers a G protein-gated, inward-rectifier
potassium (GIRK) channel response. In this study, the GIRK channel responses
of 11 SCRAs were measured using AtT20/SEPCB1 cells and the GIRK channel
fluorescent assay described in chapter 2. Potency was determined to be 5-fluoro
MDMB-PICA > 4-fluoro MDMB-BUTINACA, AB-FUBINACA > MDMB-4enPINACA > JWH-018 > AM1220 > XLR-11 > JWH-122 N-(5-chloropentyl) > WIN
55, 212-2 > UR-144 > AM1248. These experiments demonstrate that SCRA indole
or indazole carboxamides increase GIRK channel potency. Additionally, the
terminal fluorination of XLR-11 increases the GIRK channel response compared
to parent compound, UR-144. This study demonstrates the effects of SCRA
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structure on GIRK channel potency and efficacy, which can be applicable to future
studies investigating how CB1 efficacy can be regulated by intracellular signaling.
4.2 Introduction
SCRAs emerged on the market in the early 2000s as a legal alternative to
marijuana that would not appear on standard drug tests. Like THC, SCRAs bind to
the cannabinoid-type 1 (CB1) receptor; however, SCRAs are known to induce
psychosis, kidney failure, stroke, and even death.[11, 39, 137] SCRA toxicity is
hypothesized to be a result of higher CB1 receptor potency and efficacy. In animal
models, SCRAs administration enhance hypothermia onset and duration when
compared to THC, reflective of increased SCRA efficacy.[138-140]
JWH-018 was one of the first SCRAs to be identified on the illicit drug
market.[13] Its increased affinity and efficacy at the CB1 receptor are attributed to
the replacement of the morpholino group on WIN 55, 212-2 with the C3 pentyl side
chain of THC.[103, 141, 142] Clandestine manufacturers mostly produce SCRAs
with an indole or indazole core substitution because this increases the cannabinoid
potency at the CB1 receptor. These SCRAs are derivatives of WIN 55, 212-2, the
prototype aminoalkylindole with an indole core and an high affinity for the CB1
receptor.[97, 143]
UR-144 is a tetramethylcyclopropylindole developed by Abbott laboratories
and, in 2012,

identified in SCRA products purchased online.[144-146]

The

terminal fluorination of UR-144 resulted in the compound, XLR-11, which displayed
increased potency at the CB1 receptor.[102] XLR-11 is one of the SCRAs identified
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in reports of fatal overdose, is established to mediate cell apoptosis, and
precipitate acute kidney toxicity.[41, 147-149]
In 2018, Scotland reported higher incidences of prisoner aggression
partially attributed to paper mail sprayed with illicit SCRAs. A study by Norman et
al. (2020) tested some of these papers and found they contained SCRAs 5-fluoro
PICA and MDMB-4en-PINACA with a variety of other high potency SCRAs.[150]
These SCRAs are amongst the newer compounds that contain L-valinamide or Ltert-leucinamide substitutions and an indole or indazole core. When analyzed,
these SCRAs display a very high affinity for the CB1 receptor.[99, 100, 105] ABFUBINACA is another such SCRA identified in liquid formulations intended for ecigarettes.[40] Interestingly, in an adolescent animal model, AB-FUBINACA and
THC shared similar behavioral effects during drug administration; however, ABFUBINACA exposure enhanced long-term deficient in cognitive processes and
suggested to be the result of altered cannabinoid receptor signaling.[151]
The effect SCRAs have on CB1 receptor molecular mechanisms is
understudied, a consequence of an ever-expanding catalog of SCRAs. The
laboratory GIRK channel fluorescent assay described in chapter 2 can effectively
measure CB1 receptor agonism.[108, 111] This study compared 10 illicit SCRAs
to reference compound, WIN 55, 212-2, to elucidate SCRA structure on CB1
receptor-induced, GIRK channel potency, and efficacy. WIN 55, 212-2 was
selected as the reference compound because it served as the prototype for JWH018 and is well-represented in cannabinoid research.[124, 152]
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4.3 Materials and methods
Drugs and chemicals
The following compounds were purchased from Cayman Chemical (Ann
Arbor, Michigan): 4-fluoro MDMB-BUTINACA, 5-fluoro MDMB-PICA, ABFUBINACA, AM1220, AM1248, , JWH-018, JWH-122 N-(5-chloropentyl),MDMB4en-PINACA, WIN 55, 212-2, UR-144, and XLR-11. Compounds were dissolved
in DMSO at stock concentrations of 20mM to 50mM. All cannabinoids were diluted
to working concentrations in 1 mM KCl buffer solution containing MD-BLUE dye
(Molecular Devices). Controlled substances were purchased using the Walsh
Laboratory DEA license.
Data analysis
Concentration curves were determined using four-parameter, non-linear
regression analysis where EC50 is the concentration producing a 50 % increase in
the maximal response ymax (Emax). (listed below) Ymin is defined as a minimum
fluorescent GIRK channel response. Drug is the concentration, and hillslope is the
slope factor.
Relative Emax values were determined by normalizing each cannabinoid’s
peak GIRK channel response to the maximal GIRK channel response of WIN 55,
212-2 (10μM). Emax graphs represents the SCRA concentration-response
normalized to peak WIN 55, 212-2 GIRK channel response. Because the minimum
GIRK channel response can vary between SCRAs and obscure the E max effect,
minimum values were standardized. “n” represents the number of wells in which
that cannabinoid concentration was tested.
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Four-parameter Equation
𝑦 = 𝑦𝑚𝑖𝑛 +

𝑦𝑚𝑎𝑥 − 𝑦𝑚𝑖𝑛
𝐷𝑟𝑢𝑔
1 + ( 𝐸𝐶 )−𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒
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Statistical analysis
Statistical significance of the comparison of cannabinoid GIRK channel
Emaxs was determined using a one-way, multiple measures ANOVA with
significance set at p < .05. Significant differences were identified using a HolmsŜídák posthoc analysis. Data and statistical analyses were performed using
Sigmaplot 14.0.
4.4 Results
GIRK channel activity for 11 cannabinoids was measured using our
fluorescent, membrane-potential sensitive assay, and AtT20 cells transfected with
the human CB1 receptor.[108, 111] The SCRAs were divided into two primary
groups: Indole-based and Indazole-based. The Indole-based group was
subdivided

into

Adamantoylindoles

the
3)

following

subgroups:

Tetracyclopropylindoles

1)
4)

Naphthoylindoles
Indole

and

2)

Indazole

carboxamides. GIRK channel potency was defined as the SCRA concentration
producing half the maximal GIRK channel response or the EC50. All SCRAs
activated GIRK channels in a concentration-dependent manner. Figures 4.1- 4.5
compare the results of structurally similar SCRAs to WIN 55, 212-2 regarding GIRK
channel response, EC50, and Emax. Only UR-144 and AM1248 were less potent
than WIN 55, 212-2, with respective EC50s of 532nM and 2530nM. Overall, the
rank order of potencies were 5-fluoro MDMB-PICA > 4-fluoro MDMB-BUTINACA
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> AB-FUBINACA > MDMB-4en-PINACA > JWH-018 > AM1220 > XLR-11 > JWH122 N-(5-chloropentyl) > WIN 55, 212-2 > UR-144 > AM1248.
The Emax values for each SCRA were normalized to the Emax of WIN 55,
212-2, with the relative percentages available in Table 4.1.

To identify E max

differences compared to WIN 55, 212-2, a one-way ANOVA comparing the SCRA
maximum fluorescent values to WIN 55, 212-2 maximum fluorescent values
revealed most SCRAs were significantly less effective at stimulating a GIRK
channel response. The indazole carboxamide, 4-fluoro MDMB-BUTINACA, was
the only SCRA to significantly stimulate a GIRK channel response greater than
WIN 55, 212-2. Emax comparisons within-group revealed the effect of structural
changes between two similar SCRAs discussed further below.
Naphthoylindoles
Both JWH-018 and JWH-122 N-(5-chloropentyl) had smaller GIRK channel
responses compared to WIN 55, 212-2. JWH-122 N-(5-chloropentyl) was visibly
slower to reach peak GIRK channel response but maintained a stable GIRK
channel response until the end of the measurement. (Figure4.1 D) JWH-018 and
JWH-122 N-(5-chloropentyl), had higher GIRK channel potency compared to WIN
55, 212-2. (Figure 4.1E).

JWH-122 N-(5-chloropentyl) was significantly more

effective at stimulating a GIRK channel signal compared to JWH-018, which
indicates the addition of a methyl group and terminal chlorination increases GIRK
channel efficacy. (p < .05) (Figure 4.1F)
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Adamantoylindoles
The naphthoylindole, AM1220, shares a similar structure to the
adamantoylindole, AM1248, and, therefore, were compared to each other.
AM1220 and AM1248 had similar GIRK channel responses. (Figure 4.2D);
however, AM1248 (EC50: 2530nM) was much less potent than AM1220 (EC50:
172nM) and WIN 55, 212-2 (EC50: 523nM). (Figure 4.2 E) AM1220 was
significantly more effective at stimulating a GIRK channel response compared to
AM1248; however, both were significantly less effective when compared to WIN
55, 212-2. (p < .001) (Figure 4.2F).
Tetracyclopropylindoles
The GIRK channel response to XLR-11 decreased towards the end of the
measurements, whereas the GIRK channel response to UR-144 appeared more
stable. (Figure 5.3D) As mentioned above in the naphthoylindole section, different
CB1 receptor kinetics could potentially explain the difference between UR-144 and
XLR-11 GIRK channel response. XLR-11 (EC50: 214nM) was more potent at
eliciting a GIRK channel response when compared to UR-144 (EC50: 532nM) and
WIN 55, 212-2 (EC50: 523nM) (Figure 5.3E). Interestingly, the Emax results for UR144 and XLR-11 were not significantly different from each other, despite the latter
being more potent. (Figure 5.3F)
Indole Carboxamides
5-fluoro MDMB-PICA was the only indole carboxamide tested and was
compared with fluorinated indazole carboxamide, AB-FUBINACA. 5-fluoro MDMBPICA (EC50: 3.33nM) was more potent compared to WIN 55, 212-2 (EC50: 523nM)
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and AB-FUBINACA (EC50: 18.1nM). (Figure 5.4D & Figure 5.4 E) The Emax of 5fluoro MDMB-PICA was significantly larger than AB-FUBINACA; however, it was
not significantly different from WIN 55, 212-2. Additionally, the Emax of ABFUBINACA was not significantly different from WIN 55, 212-2, despite being less
than 5-fluoro MDMB-PICA. (Figure 5.4 F)
Indazole Carboxamides
In a recent analysis of SCRA products, the indazole carboxamides, 4 fluoroMDMB-BUTINACA and MDMB-4en-PINACA, were identified. Both stimulated a
more robust GIRK channel response that peaked at lower concentrations than
other SCRAs. (Figure 4.5D). 4-fluoro MDMB-BUTINACA (EC50: 4.97nM) was more
potent than MDMB-4en-PINACA (EC50: 19.7nM) (Figure 4.5E), with an EC50 value
similar to 5-fluoro MDMB-PICA (EC50: 3.33nM). (Table 4.1) 4-fluoro MDMBBUTINACA was significantly more efficacious at stimulating a GIRK channel
response in comparison to MDMB-4en-PICA (p < .05) and WIN 55, 212-2. (p <
.001)(Figure 4.5F) It is worth noting the Emax values of 4-fluoro MDMB-BUTINACA
and 5-fluoro MDMB-PICA were not significantly different from each other, and they
shared similar potency; however, only 4-fluoro MDMB-BUTINACA produced a
significantly larger GIRK channel response in comparison to WIN 55, 212-2. (p <
.001)
Comparison to THC and AEA
A one-way ANOVA was performed to determine significant differences in
Emax values comparing SCRAs to the endocannabinoid, AEA, and the
phytocannabinoid, THC. The analysis revealed that AEA and THC were
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significantly less effective at stimulating the GIRK channel response in comparison
to all SCRAs. (p < .001)
4.5 Discussion
The growing list of novel SCRAs and the ease of purchasing these products
online has accumulated into baffling overdose cases in which medical personnel
struggle to develop a treatment plan. To better treat the impact of SCRA toxicity,
researchers study the molecular mechanisms driven by CB1 receptor
agonism.[12] These experiments investigate the CB1 receptor-induced GIRK
channel response to a series of SCRAs with different structural characteristics.
Overall, most SCRAs tested had a higher affinity for the CB1 receptor when
compared to WIN 55, 212-2; however, only 4-fluoro MDMB-BUTINACA had an
Emax that was significantly greater than WIN 55, 212-2.
There is increasing evidence that cannabinoids, SCRAs included, can
induce biased signaling.[94, 121, 153, 154] In this study, XLR-11 was more potent
than its parent compound, UR-144; therefore, supporting the fluorination of a
SCRA increases potency. Interestingly, the GIRK channel response for XLR-11
has a greater decrease in fluorescence when compared to UR-144. This effect
could be CB1 receptor rapid desensitization modulated by the recruitment of βarr2,
as the binding of βarr2 to the CB1 receptor prevents the binding of G proteins.[58,
155].
CB1 receptor desensitization occurs when βarr2 is recruited to the
phosphorylated, proximal c-terminus located on the intracellular side of the
cell.[156, 157] An electrophysiology study by Jin et al. (1999) reported
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approximately a 40% decrease in GIRK channel current at 80 seconds post WIN
55, 212-2 exposure. The decrease in GIRK channel current was attributed to βarr2
binding to the phosphorylated CB1 receptor results in the attenuation of the WIN
55, 212-2 induced GIRK channel signal via receptor desensitization. [51] The
attenuation of the GIRK channel response would decrease Emax values, such as
the case of the SCRAs tested in this current study. Explicitly, XLR-11 biased
towards βarr2 recruitment over Gαi, and the recruitment of βarr2 does not mediate
CB1 receptor internalization. [153, 154] Although AB-FUBINACA and 5-fluoro
MDMB-PICA had lower EC50 values, the GIRK channel response was not
significantly different from WIN 55, 212-2. In a study by Patel et al. (2020), both 5fluoro MDMB-PICA and AB-FUBINACA were more potent recruiters of βarr2 when
compared to WIN 55, 212-2, and thus, more likely to induce CB1 receptor
desensitization.[153]
In conclusion, the structure of a SCRA can modulate the of outcome CB1
receptor signaling through potential βarr2 recruitment leading to receptor
desensitization. Along with being expressed in the CNS, GIRK channels are
expressed in the heart.[69, 72] This is particularly relevant to the physiological
effects seen in SCRA (i.e.seizures and cardiovascular events), as the decline in
GIRK channel activity can translate to the increase in excitatory neurotransmitter
release.[15, 158, 159]
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Figure 4.1: GIRK channel responses and cannabinoid structures (JWH
compounds). (A) WIN 55, 212-2 (B) JWH-018 (C) JWH-122 N-(5-chloropentyl)
(D) Comparison of max GIRK channel responses. (E) Comparison of EC50s
demonstrating cannabinoid potency (F)Comparison of cannabinoid Emax relative
to WIN 55, 212-2 Error bars represent standard error of mean.↓ Indicates
application of WIN 55, 212-2 (n = 5), JWH-018 (n = 4), JWH-122 N-(5chloropentyl) (n = 4),
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Figure 4.2: GIRK channel responses and cannabinoid structures (AM
compounds). A) WIN 55, 212-2 B) AM1220 C) AM1248 D) Comparison of max
GIRK channel responses. (E) Comparison of EC50s demonstrating cannabinoid
potency (F)Comparison of cannabinoid Emax relative to WIN 55, 212-2 Error
bars represent standard error of mean.↓ Indicates application of WIN 55, 2122 (n = 5), AM1220 (n = 5), AM1248 (n = 5)
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Figure 4.2: GIRK channel responses and cannabinoid structures. A) WIN 55,
212 B) AM1220 C) AM1248 D) Comparison of EC50s demonstrating
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Figure 4.3: GIRK channel responses and cannabinoid structures
(Tetracyclopropylindoles). A) WIN 55, 212-2 B) UR-144 C) XLR-11 (D)
Comparison of max GIRK channel responses. (E) Comparison of EC50s
demonstrating cannabinoid potency (F) Comparison of cannabinoid Emax
relative to WIN 55, 212-2 Error bars represent standard error of mean.↓
Indicates application of WIN 55, 212-2 (n = 5), UR-144 (n = 4), XLR-11 (n = 5)
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Figure 4.3: GIRK channel responses and cannabinoid structures. A) WIN 55,
212 B) UR-144 C) XLR-11 D) Comparison of EC50 demonstrating cannabinoid
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Figure 4.4 GIRK channel responses and cannabinoid structures
(Carboxamides 1). (A) WIN 55, 212-2 (B) AB-FUBINACA (C) 5-fluoro MDMBPICA (D) Comparison of max GIRK channel responses. (E) Comparison of
EC50s demonstrating cannabinoid potency (F)Comparison of cannabinoid Emax
relative to WIN 55, 212-2 Error bars represent standard error of mean.↓
Indicates application of WIN 55, 212-2 (n = 5), AB-FUBINACA (n = 6), 5-fluoro
MDMB-PICA (n = 4)
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Figure 4.5: GIRK channel responses and cannabinoid structures
(Carboxamides 2). (A) WIN 55, 212-2 (B) 4-fluoro MDMB-BUTINACA (C)
MDMB-4en-PINACA D) Comparison of max GIRK channel responses. (E)
Comparison of EC50s demonstrating cannabinoid potency (F) Comparison of
cannabinoid Emax relative to WIN 55, 212-2 Error bars represent standard error
of mean.↓ Indicates application of WIN 55, 212-2 (n = 5), 4-fluoro MDMBBUTINACA (n = 6), MDMB-4en-PINACA (n = 6)
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Table 4.1: SCRAs potency and efficacy
Cannabinoid

EC50 (nM)
± S.E.M

Emax (%)
± S.E.M

Aminoalkylindole
Prototype

WIN 55, 212-2

523 ± 68.0

Reference

Napthoylindoles

JWH-018

46.3 ± 4.8

55.8 ±
6.13*

JWH-122 N-(5chloropentyl)

231 ± 35.4

74.0 ± 3.41*

AM1220

172 ± 6.2

78.3 ±
2.72*

Adamantoylindole

AM1248

2530 ± 805

63.5 ±
3.90*

Tetracyclopropylindoles

UR-144

532 ± 33.9

51.3 ±
3.26*

XLR-11

214 ± 14.9

53.0 ±
2.59*

5-fluoro-MDMB-PICA

3.33 ± 0 .3

108 ± 4.27

AB-FUBINACA

18.1 ± 7.0

89 ± 2.93

4-fluoro-MDMBBUTINACA

4.97 ± 2.6

115 ± 2.92†

MDMB-4en-PINACA

19.7 ± 2.9

101 ± 5.21

Class
Indole-Based

Indole Carboxamide
Indazole-Based
Indazole Carboxamide

* p < .001 compared to WIN 55, 212-2
† p < .05 compared to WIN 55, 212-2
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.1 Conclusion
The changing legal and social perception of Cannabis has precipitated
interest in cannabinoid therapeutics, with a particular focus on pain management.
The ease of online shopping and the legal loopholes facilitating the manufacturing
of novel SCRAs have resulted in numerous overdose cases with potentially lethal
outcomes. Together, these realizations draw attention to the need to understand
the molecular mechanisms underlying CB1 receptor signaling.
This thesis elucidates CB1 receptor-induced, GIRK channel activity by a
series of chemically distinct and similar cannabinoids by addressing the following:
1) establishing a GIRK channel assay 2) outlining the GIRK channel response to
cannabinoids representative of the eicosanoid, classical, non-classical, and
aminoalkylindole classes. 3) investigating the effect of illicit SCRAs on GIRK
channel activation
GIRK channels are activated by agonists binding to the CB1 receptor. The
use of fluorescent, MP-sensitive dye allowed for the GIRK channel response to be
recorded in real-time. CB1 receptor-induced, GIRK channel activity was verified by
inhibiting the WIN 55, 212-2 response by either pretreating the AtT20/CB1 cells
with GIRK channel blocker, tertiapin, or the CB1 receptor antagonist, SR141716.
Overall, chapter 2 reports a capable GIRK channel assay sensitive to CB1 receptor
activity.
66

A similar structure defines the four primary groups of cannabinoids. The
classical cannabinoids include compounds derived from the Cannabis plant (i.e.,
THC, CBD, and THCA-A). The eicosanoid, AEA, is synthesized endogenously in
humans. CP 55, 940 is a notable synthetic, non-classical cannabinoid, and WIN
55, 212-2, is the aminoalkylindole prototype. Chapter 3 reports that neither THCAA nor CBD produces a GIRK channel response reflective of activation. CP 55, 940
and WIN 55, 212-2 displayed a lower EC50 values for the CB1 receptor compared
to AEA and THC. Additionally, both synthetic cannabinoids were more effective at
generating a GIRK channel response, potentially due to differential G protein
signaling.
Through applying the GIRK channel assay to the study of SCRA-modulated
CB1 receptor signaling, differences were uncovered regarding cannabinoid
structure. Chapter 4 revealed that an indole or indazole core in a SCRA greatly
increased CB1 receptor potency in addition to terminal fluorinations. Also, SCRA
potency did not determine the magnitude of the GIRK channel response,
potentially due to CB1 receptor desensitization.
In conclusion, the cannabinoids tested in these studies underscore the
importance of understanding CB1 receptor signaling. Factors such as CB1
receptor internalization and desensitization can modulate the effectiveness of a
cannabinoid at signaling the GIRK channel response. These factors play a crucial
role in determining the physiological response to cannabinoids, and therefore
should be further investigated.
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5.2 Future directions
The SEPCB1 receptor construct was developed by Dr. Andrew Irving
(University College Dublin) to measure cannabinoid-induced, CB1 receptor
internalization.[160] The SEPCB1 construct is a pH-sensitive variant of GFP
located on the N-terminus of the receptor. This construct will emit a fluorescent
signal when expressed on the surface of the cells; however, as the receptor
internalizes, the signal will decrease due to the acidic environment located within
the cells.[160, 161] The Walsh laboratory received the SEPCB1 construct, which
was used to create the AtT20/SEPCB1 cells used in chapters 3 and 4. Additionally,
the SEPCB1 construct was transfected into HEK293 cells (HEK293/CB1). A pilot
experiment was conducted measuring CB1 receptor internalization over time in
response to cannabinoids. Using the EVOS FL2 Auto live cell imaging system,
fluorescent images were taken of HEK293/SEPCB1 cells in control, 2μM WIN 55,
212-2, or 1μM CP 55, 940 conditions at 0, 5, 10, 20, and 30 minute time points.
(Figure 5.1)
For future directions, I propose expanding these experiments to include
THC, JWH-018, XLR-11, AB-FUBINACA, and 5-fluoro MDMB PICA based on the
previous experiments and their relevance to the field of research. The change in
fluorescence in these images can be quantified using imaging programs like Image
J. Data from these experiments could help define cannabinoid-dependent, CB1
receptor internalization which will determine signaling bias within β-arrestin
recruitment and between Gi protein signaling. Additional GIRK channel assays
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using HEK293/SEPCB1 cells will be necessary to maintain consistency between
the different methods.
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A

B

C

Figure 5.1: Prelimary data from HEK293/SEPCB1 cannabinoid
experiments. Change in fluorescence over 30 minutes representative of
CB1 receptor internalization. (A) Control (B) 2μM WIN 55, 212 (C) 1μM CP
55, 940
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